RU-58841

RU-58841: A Comprehensive Exploration of Its Therapeutic Potential[edit]

RU-58841, also known as PSK-3841 or HMR-3841, is an experimental drug with potential applications in the management of conditions like acne, androgenetic alopecia (male-pattern baldness), and hirsutism (excessive hair growth). This compound, part of a class of non-steroidal anti-androgens, shares structural similarities with RU-58642 but stands out due to its distinct side-chain. The therapeutic indications and structural characteristics of RU-58841 offer valuable insights into the realm of anti-androgenic drug development.

Chemical Characteristics[edit]

RU-58841 is chemically delineated by its unique molecular structure, which differentiates it from related compounds. While its core structure bears resemblance to RU-58642, its distinct side-chain endows it with specific physicochemical and therapeutic properties.

The compound's categorization as a non-steroidal anti-androgen places it in the same league as drugs like nilutamide. Nilutamide, in turn, is closely related to other anti-androgens like flutamide and bicalutamide.

Therapeutic Mechanism[edit]

Non-steroidal anti-androgens like RU-58841 act by binding to androgen receptors. By doing so, they prevent endogenous androgens, like testosterone and dihydrotestosterone, from exerting their effects. This mechanism of action can be particularly useful in conditions exacerbated by androgens, such as androgenetic alopecia or acne^[1].

Comparative Analysis with Enzalutamide[edit]

Enzalutamide is a more contemporary anti-androgen drug. It is primarily known for its role in the treatment of prostate cancer. While both RU-58841 and enzalutamide target the androgen receptor, enzalutamide's more pronounced impact in prostate cancer treatment contrasts with the dermatological indications of RU-58841^[2].

Clinical Implications and Research Findings[edit]

RU-58841, due to its anti-androgenic properties, has garnered interest as a potential topical treatment for:

Acne: By mitigating androgenic stimulation of sebaceous glands, which can lead to acne formation.
Androgenetic alopecia: Offering a potential solution to counteract hair follicle miniaturization induced by androgens.
Hirsutism: By reducing excessive hair growth that may be potentiated by heightened androgenic activity.

Several studies have delved into the potential of RU-58841 in these domains, underscoring its therapeutic promise^[3].

Conclusion[edit]

RU-58841 represents an intriguing prospect in the world of non-steroidal anti-androgens, particularly for dermatological applications. As research continues to unfold, a clearer understanding of its safety, efficacy, and potential place in therapeutic regimens will emerge.

References[edit]

↑ Baker HW, Burger HG, de Kretser DM, Hudson B, Rennie GC, Paulin JM. (1976). Changes in the pituitary-testicular system with age. Clin Endocrinol (Oxf). 5(4):349-72.
↑ Tran C, Ouk S, Clegg NJ, et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 324(5928):787-90.
↑ Obana N, Chang C, Uno H. (1997). Inhibition of hair growth by testosterone in the presence of dermal papilla cells from the frontal bald scalp of the postpubertal stumptailed macaque. Endocrinology. 138(1):356-61.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Baker HW, Burger HG, de Kretser DM, Hudson B, Rennie GC, Paulin JM. (1976). Changes in the pituitary-testicular system with age. Clin Endocrinol (Oxf). 5(4):349-72.

[2] Tran C, Ouk S, Clegg NJ, et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 324(5928):787-90.

[3] Obana N, Chang C, Uno H. (1997). Inhibition of hair growth by testosterone in the presence of dermal papilla cells from the frontal bald scalp of the postpubertal stumptailed macaque. Endocrinology. 138(1):356-61.

[1]

[2]

[3]